Yahoo
    NasdaqCM - Delayed Quote USD

    Xenetic Biosciences, Inc. (XBIO)

    2.0500 -0.0700 (-3.30%)
    At close: October 30 at 4:00:01 PM EDT
    Loading Chart for XBIO
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

    Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
    ACCESS Newswire 16d ago
    Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake

    Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake
    InvestorsHub 1mo ago
    Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

    Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
    ACCESS Newswire 1mo ago
    Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

    Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
    ACCESS Newswire 4mo ago
    Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

    Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
    ACCESS Newswire 5mo ago
    Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

    Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
    ACCESS Newswire 6mo ago
    Xenetic Biosciences: Q3 Earnings Snapshot

    Xenetic Biosciences: Q3 Earnings Snapshot
    Associated Press Finance 11mo ago
    Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition

    Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
    Benzinga 1mo ago
    Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

    Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
    ACCESS Newswire 4mo ago
    Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

    Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
    ACCESS Newswire 2mo ago
    Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

    Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
    ACCESS Newswire 7mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: